• Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

    ソース: Nasdaq GlobeNewswire / 29 3 2023 06:00:00   America/Chicago

    BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a virtual fireside chat during the Guggenheim Genomic Medicines and Rare Disease Conference on Tuesday, April 4, 2023 at 9:00 a.m. Eastern Time.

    A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.

    About Entrada Therapeutics
    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as our partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1).

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

    Investor and Media Contact
    Karla MacDonald
    Chief Corporate Affairs Officer
    kmacdonald@entradatx.com


    Primary Logo

シェアする